Radiation therapy, a mainstay for anti-tumor therapeutic regimens for a variety of tumor types, triggers tumor cell apoptotic pathways by either directly eliciting DNA damage or indirectly inducing the formation of oxygen radicals. In an effort to augment radiation therapy, we generated a double E1B 19 kDa-and E1B 55 kDa-deleted oncolytic adenovirus (AdÀDE1B19/55). In combination with radiotherapy, greater cytotoxicity was observed for AdÀDE1B19/55 than for the single E1B 55 kDa-deleted oncolytic Ad (AdÀDE1B55). Consistent with this observation, higher levels of p53, phosphop53, phospho-Chk1, phospho-Chk2, PI3K (phosphatidylinositol-3-kinase), phospho-AKT, cytochrome c, and cleavage of PARP (poly (ADP-ribose) polymerase) and caspase-3 were observed in cells treated with AdÀDE1B19/55 compared with those treated with AdÀDE1B55, indicating that the E1B 19 kDa present in AdÀDE1B55 may partially block radiation-induced apoptosis. A significant therapeutic benefit was also observed in vivo when oncolytic Ads and radiation were combined. Tumors treated with AdÀDE1B19/55 and radiation showed large areas of necrosis and apoptosis with the corresponding induction of p53. Finally, consistent with in vitro observations, the combination of AdÀDE1B19/55 and radiation was more efficacious than the combination of AdÀDE1B55 and radiation. Taken together, these results present a strong therapeutic rationale for combining radiation therapy with E1B 19 kDadeleted oncolytic Ad.
Introduction
Recent research efforts have focused on the feasibility of combining multiple modalities to improve the therapeutic value of current standard therapies, such as chemotherapy and radiotherapy. Radiotherapy uses ionizing radiation to destroy malignant tumor cells. Although higher doses of radiation can exert greater anti-tumor effects, the dosage is limited by the potential toxicity associated with normal tissue damage within the radiation field. Thus, combination therapies that can enhance standard radiotherapy regimens without increasing potential toxicities are needed.
Adenovirus (Ad)-mediated oncolytic treatment and gene therapy have emerged as promising cancer treatment modalities. Oncolysis results from a replicating virus that lyses infected tumor cells and releases viral progeny to further the infection and killing of neighboring cancer cells. E1B 55 kDa-deleted Ad was initially used in p53-null cancer cells, but subsequent studies have shown that the observed oncolysis was a p53-independent event. Further analysis also revealed that the loss of E1B 55 kDa-mediated late viral RNA export (rather than p53 degradation) was the major determinant of tumor-selective replication of AdÀDE1B55. 1 In recent years, a therapeutic regimen combining radiation with oncolytic Ad has shown some promise in controlling tumor cell growth. [2] [3] [4] An E1B 55 kDa-deleted oncolytic Ad, dl1520 (ONYX-015), has been shown to potentiate radiation therapy, 5 leading to several pre-clinical studies examining the value of combining these two modalities. [6] [7] [8] [9] Intra-arterial injections of dl1520, in conjunction with total body irradiation (5 Gy), result in enhanced anti-tumor efficacy in p53 functional human malignant glioma xenograft models. 5 Moreover, Freytag et al. 4 have shown that oncolytic Ad-mediated suicide gene therapy augments the effectiveness of pancreatic radiotherapy without resulting in significant toxicity. Enhanced antitumor efficacy has also been shown in combination studies using Ad5ÀD24RGD (Rb-binding mutant oncolytic Ad with an RGD (arginyl-glycyl-aspartic acid) motif in the HI-loop), CV706 (PSA (prostate-stimulating antigen)-selective oncolytic Ad) and Ad5-CD/TKrep Ads (oncolytic Ad containing a cytosine deaminase and herpes simplex virus thymidine kinase fusion gene).
The adenoviral E1B 19 kDa protein, a homolog of antiapoptotic Bcl-2-related protein, is a potent inhibitor of apoptosis. 13, 14 Interestingly, the anti-apoptotic effect of the E1B 19 kDa protein is functionally equivalent to that of Bcl-2 in terms of its ability to inhibit apoptosis induced by treatment with ionizing radiation and chemotherapeutic agents. 15, 16 Previously, we studied the effects of an E1B-defective Ad in normal human cells and in malignant tumors, 17 and showed that an E1B 19 kDa and E1B 55 kDa double-deleted oncolytic Ad, AdÀDE1B19/55, led to improved cytotoxicity and apoptosis compared with a E1B 55 kDa single-deleted oncolytic Ad, AdÀDE1B55. In addition, in vivo, we reported greater anti-tumor efficacy after intratumoral injections.
To date, a systematic therapeutic analysis of combining adenoviral E1B 19 kDa and 55 kDa gene-modified adenoviral vectors with radiotherapy has not been carried out. As apoptosis is an important pathway of cell death after radiotherapy, strategies aimed at increasing the apoptotic potential by combining oncolytic Ad and radiation are highly desirable. In the current study, we investigated the anti-tumor effects of treatment combining radiotherapy and genetically attenuated adenoviral vectors containing different combinations of E1B genes.
Results

Effect of combining AdÀDE1B55 or AdÀDE1B19/55 with radiotherapy in vitro
Before examining the combination potential of oncolytic Ads and radiotherapy, we first infected cancer and normal cells with AdÀDE1B55 or with AdÀDE1B19/55 to evaluate their effects as single agents. AdÀDE1B19/55 was more effective than AdÀDE1B55 in killing both A549, U343, Hep3B and C33A cancer cell lines and the WRL68 normal cell line (Po0.05) (Figure 1a ). This finding was confirmed in a flow cytometry study showing that treatment of U343 cells with Ad-DE1B19/55 at a multiplicity of infection (MOI) of 10 significantly increased the number of apoptotic cells compared with an equal treatment with AdÀDE1B55. As shown in Figure 1b , the apoptotic fraction (Annexin V-positive and propidium iodide-negative) was 79.9% in cells infected with AdÀDE1B19/55 compared with 15.5% of AdÀDE1B55-infected cells. These results are consistent with earlier reports showing that the loss of the E1B 19 kDa protein enhances apoptosis and adenoviral lytic potency. 17 Next, to evaluate the potential of combination therapy, cells were infected with AdÀDE1B55 or AdÀDE1B19/55 for 24 h at an MOI of 2 or 5 for A549 and U343, 0.1 or 0.3 for Hep3B, 0.5 or 1 for C33A and 0.1 or 0.5 for WRL68 cells and then treated with 5 or 10 Gy of ionizing radiation for an additional 48 h. As shown in Figure 2 and Supplementary data 1, treatment with radiation alone (5, 10 and 15 Gy) led to a dose-dependent inhibition of cell growth in all cell lines tested. Moreover, increased cytotoxicity was observed in all cancer cell lines treated with AdÀDE1B55 or AdÀDE1B19/55 and radiation. For example, in C33A cells, radiation alone caused 28.7 and 44.2% growth inhibition at 5 and 10 Gy, respectively. Similarly, infection with AdÀDE1B55 and AdÀDE1B19/55 at an MOI of 0.5 also caused modest growth inhibition of 15.4 and 24.8%, respectively. When combined, however, 5 Gy of radiation and AdÀDE1B55 or AdÀDE1B19/55 at an MOI of 0.5 resulted in growth inhibition of 35.5 and 55.8%, respectively. Similar growth inhibition was observed in the cancer cell lines A549, U343 and Hep3B. In marked contrast, combination therapy with oncolytic Ad and radiation did not increase cytotoxicity relative to radiation alone in WRL68 normal cells.
Enhanced apoptosis by combining AdÀDE1B19/55 with radiation Induction of apoptosis represents a potential mechanism of radiation-enhanced cancer cell killing by oncolytic Ad. To further test whether the observed increase in tumor cell killing was because of enhanced apoptosis, we quantified the sub-G 1 population of AdÀDE1B55-or AdÀDE1B19/55-infected U343 cells at 24 h after infection and at 48-72 h after subsequent treatment with radiotherapy by fluorescence-activated cell-sorting analysis. As shown in Table 1 , radiation, AdÀDE1B55 and AdÀDE1B19/55 alone induced 7.8, 3.0 and 17.5% sub-G 1 accumulation in U343 cells at the 48 h time point and 26.0, 7.3 and 36.6% sub-G 1 accumulation at 72 h after treatment, respectively. In contrast, the sub-G 1 population in the AdÀDE1B19/55 and radiation combination group was significantly higher at 29.6 and 53.7% at 48 and 72 h after irradiation, respectively. Interestingly, U343 and C33A cells treated with AdÀDE1B55 and radiation showed smaller sub-G 1 populations than the same cells treated with radiation alone. The enhanced apoptosis elicited by the combination of AdÀDE1B19/55 and radiation was also observed in A549, Hep3B and C33A cancer cells.
The enhancement of apoptosis by AdÀDE1B19/55 in combination with radiation was further verified by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (Figure 3 ). When combined with radiation, AdÀDE1B19/55 significantly increased the percentage of apoptotic cells. More specifically, 43.10% of AdÀDE1B19/55-infected A549 cells stained positive for TUNEL when co-treated with radiation, whereas only 23.30% of AdÀDE1B19/55-infected cells and 19.21% of radiation-treated cells were TUNELpositive. In contrast, when AdÀDE1B55 infection was combined with radiation, the TUNEL-positive cell population slightly decreased to 18.00% compared with the 19.21% for the radiation-alone group. TUNEL assays with A549 cells produced results comparable with those obtained in U343, Hep3B and C33A cells.
Enhanced activation of the apoptotic signal transduction pathway by combining AdÀDE1B19/55 with radiation Radiation can induce DNA damage and trigger p53-mediated apoptosis, resulting in mitochondrial damage with the release of cytochrome c. [18] [19] [20] To further elucidate the apoptotic signal transduction pathway activated by the combination of oncolytic Ad and radiation, we first carried out a western blot analysis to evaluate the activation of p53, phospho-p53 (p53 phosphorylated at serine 15), phospho-Chk1, phospho-Chk2, phosphatidylinositol-3-kinase (PI3K) and phospho-AKT (Figure 4a ).
Both p53 and phospho-p53 expression was substantially elevated in cells treated with either AdÀDE1B55 or AdÀDE1B19/55 alone. Infection with AdÀDE1B19/55 and radiation yielded a greater increase in p53 and phopho-p53 expression than infection with AdÀDE1B55 and radiation. Expression levels of phospho-Chk1, phospho-Chk2, PI3K and phospho-AKT were similarly elevated in cells treated with AdÀDE1B19/55 and radiation, suggesting the role of PI3K-AKT-Chk1/Chk2-p53 pathway in response to combined AdÀDE1B19/55 and radiation treatment. Release of cytochrome c from mitochondria to cytosol, activation of Bax, and cleavage of PARP (poly (ADP-ribose) polymerase) and caspase-3 were also observed in cells treated with AdÀDE1B19/55 alone and those treated with Ad-DE1B19/55 and radiation (Figure 4b ). These results indicate that enhanced apoptosis contributed significantly to the increased cell death elicited by the combination of E1B 19 kDa-deleted oncolytic Ad and radiation.
Combination of oncolytic Ad with local tumor irradiation significantly increases anti-tumor effects and confers a survival advantage
After our in vitro analysis, we investigated whether the increase in cancer cell-killing efficacy by the combination therapy could translate to enhanced anti-tumor efficacy in vivo. To show any additive or synergistic effects of combination therapy in vivo, we selected a dose of Ad that was fivefold lower than the effective dose in the single-agent treatment experiments. After they reached 80-100 mm 3 in volume, subcutaneously implanted C33A tumors were randomized and treated with PBS (phosphate-buffered saline), AdÀDE1B55 or AdÀDE1B19/55 alone, or in combination with radiation (10 Gy). Local tumor irradiation was preceded by three sequential injections of oncolytic Ads 24 h before. As seen in Figure  5a , at 31 days post-treatment, treatment with AdÀDE1B55, AdÀDE1B19/55, or radiation alone resulted in tumor growth inhibition of 36, 48 and 65%, respectively. In When tumor growth delay was assessed, the anti-tumor effect was found to be synergistic in both combination treatments relative to treatment with individual agents alone. The EF (enhancement factor) for the combination treatment of AdÀDE1B55 and radiation or AdÀDE1B19/55 and radiation versus radiation alone was 1.17 and 3.17, respectively. 21, 22 On the basis of definitions of EF 42 as synergistic and 1oEFo2 as additive, AdÀDE1B19/55 and radiation together acted synergistically to boost anti-tumor efficacy.
The Kaplan-Meier survival data analysis ( Figure 5b ) also showed a significant advantage for combining either AdÀDE1B55 or AdÀDE1B19/55 with radiation over each To better understand the mechanism of tumor response, we performed histological and immunohistochemical analysis for adenoviral E1A protein in tumor tissues. Observation of morphological structures using hematoxylin and eosin staining revealed no obvious differences between irradiated and non-irradiated control tumors, with both showing a typical high cell density. In contrast, tumors treated with oncolytic Ads and radiation displayed large necrotic cores (Figure 6a ). Immunohistochemistry confirmed the presence of Ad virus in all infected tumors and showed an increase in adenoviral distribution in tumors treated with Ad-DE1B19/55 and radiation. Interestingly, we observed a large concentration of adenoviral particles localized in a (Figure 6a ; Ad E1A Â 100). To assess the role of apoptosis in vivo, we carried out the TUNEL assay and immunostaining for p53 on tumor sections 3 days after radiation in all six treatment groups (Figure 6b ). Apoptotic nuclei were visualized using the 3, 3 0 -diaminobenzidine substrate. As shown in Figure 6b , the number of TUNEL-positive cells was notably elevated in tumors treated with the combination of AdÀDE1B19/55 and irradiation (10 Gy). Similar to that observed in vitro, p53 expression was also substantially increased in AdÀDE1B19/55 and irradiation-treated tumors. These results were also consistent with our in vitro results showing that combination therapy with AdÀDE1B19/55 and irradiation increased the induction of apoptosis.
Discussion
Enhanced anti-tumor efficacy has been previously observed with oncolytic Ads when combined with chemotherapeutic agents or radiation in several tumor models. 16, 23, 24 Moreover, preliminary clinical trial evidence has shown that for patients with head-and-neck cancer, ONYX-015 in combination with 5-FU (fluorouracil) and cisplatin resulted in more objective responses than virus alone. 25 This result highlights the potential benefits of combining oncolytic Ads with standard tumor therapies.
Previously, we have shown that AdÀDE1B19/55 exhibited marked cytolytic activity and enhanced apoptosis. 17 Radiation therapy-induced cell death is dependent upon direct DNA damage or indirect mediation of the formation of oxygen radicals that disrupt cellular pathways, ultimately leading to the induction of apoptosis. 19, 26 Therefore, the presence of the adenoviral early protein, E1B 19 kDa, which is a strong anti-apoptotic agent present in oncolytic Ad, could greatly reduce the anti-tumor effect caused by radiotherapy and undermine the effectiveness of combination therapy. To overcome this potential difficulty, we investigated E1B-mutant oncolytic Ads in combination with radiation. Ad-ΔE1B55 (7) Ad-ΔE1B19/55 (7) Ad-ΔE1B55 + Radiation (7) Ad-ΔE1B19/55 + Radiation (7) Radiation (7) 10 Gy treatment 1 X 10 8 PFU injection 
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An enhanced anti-cancer effect was seen when oncolytic Ads were combined with radiotherapy for multiple tumor cells. Cancer cells infected for 24 h with either AdÀDE1B55 or AdÀDE1B19/55 Ad before treatment with radiotherapy displayed greater cell death than those treated with single agents alone. Moreover, we found that AdÀDE1B19/55 had greater efficacy when combined with radiotherapy than AdÀDE1B55 (Figure 2) . The enhanced efficacy of AdÀDE1B19/55 oncolytic Ad and radiotherapy was shown in multiple cancer cell lines irrespective of their radiation sensitivity. Interestingly, the enhanced cell killing of the oncolytic Ad in combination with radiation was independent of p53 status. As previously shown, the p53 tumor suppressor pathway is inactivated in nearly all human tumors, either through direct mutation of p53 or the loss of upstream regulators, such as p14 ARF , or downstream p53 effectors, such as Bax. 27 In addition, the oncolysis of E1B 55 kDa-deleted oncolytic Ad is not dependent upon p53 status in cancer cells; nuclear export of late viral RNA is actually the major determinant of tumor-selective oncolysis. 1 As tumor cells have altered mechanisms for RNA export, these p53-independent mechanisms of tumor-selective replication of E1B 55 kDa-deleted oncolytic Ad may result in efficient oncolysis by AdÀDE1B55 or AdÀDE1B19/55 oncolytic Ad in p53-mutant cells.
We next investigated the role of apoptosis in mediating the combination therapy-induced cell response. First, we assessed the sub-G 1 population at 48 and 72 h after radiation treatment, because ionizing radiation has been noted to induce an apoptosis peak at X48 h in many cell lines. 15 As shown in Table 1 , AdÀDE1B19/55 infection resulted in a significant increase in the sub-G 1 population when combined with radiation. In strong contrast, the sub-G 1 population was smaller in U343 and C33A cells treated with AdÀDE1B55 and radiation than in those treated with radiotherapy alone (at 48 and 72 h). Furthermore, enhanced levels of p53, phospho-53, phospho-Chk1, phospho-Chk2, PI3K, phospho-AKT, and cleavage of PARP and caspase-3 were observed when cells were treated with AdÀDE1B19/55 and radiation. These data show that these molecular alterations are associated with active induction of apoptosis after combined treatment with AdÀDE1B19/55 and radiation.
In agreement with these findings, we also observed that AdÀDE1B19/55 infection in combination with radiation resulted in a significant increase in the percentage of TUNEL-positive apoptotic cells compared with cells treated with radiation alone, whereas combination treatment with AdÀDE1B55 and radiation only modestly increased the apoptotic cell ratio compared with treatment with radiation alone (Figure 3) . These results are consistent with our fluorescence-activated cell-sorting analysis, showing that the E1B 19 kDa protein present in AdÀDE1B55 oncolytic Ad may play a critical role in blocking the effect of irradiation-induced apoptosis. In support of these results, Huang et al. 15 found that high levels of E1B 19 kDa expression inhibit apoptosis induced by treatment with g-radiation, providing evidence that both E1B 19 kDa and Bcl-2 are indistinguishable in their ability to regulate the cell death effector machinery. Taken together, these findings support the conclusion that the deletion of anti-apoptotic protein E1B 19 kDa in oncolytic Ad increased the rate of cytotoxicity with an active induction of apoptosis when combined with radiation.
The synergistic anti-tumor efficacy observed in vitro with AdÀDE1B19/55 and radiation also translated into in vivo. The combined treatment with oncolytic Ads and radiation resulted in significantly greater tumor growth inhibition and survival relative to radiation or oncolytic AdÀmediated cancer gene therapy alone in C33A cells, a human cervical cancer xenograft model ( Figure 5) . Moreover, the combination of AdÀDE1B19/55 and radiation was superior to the combination of Ad-DE1B55 and radiation or treatment with radiation or either oncolytic Ad alone. Increased necrosis and apoptosis were also observed in histological sections taken from tumors after the combination treatment. These findings are consistent with our previously published results on the enhancement of the anti-tumor effect with increased apoptotic pathways. 16, 28 Specifically, the combination of radiation with AdÀDE1B19/55 caused a greater induction of apoptosis than that with AdÀDE1B55, ultimately resulting in a greater therapeutic impact. This result is in good agreement with an earlier report showing that no significant increase in activation of apoptosis was observed in tumors treated with ONYX-015 (molecularly identical to AdÀDE1B55) and radiation compared with controls treated with radiation alone. 5 The observed boost in anti-tumor efficacy by the combination of E1B 19 kDa-deleted oncolytic Ad and radiation may help to explain the interactive effects of the combined treatment. Ionizing radiation may improve the induction of apoptosis, leading to better tumor interstitial viral spread. 11, 16, 29, 30 Apoptosis-mediated degradation of tumor tissues could lead to a favorable environment, with voided spaces promoting viral spread by the process of diffusion. Our immunohistochemistry findings using an antibody detecting adenoviral E1A protein in tumor tissues clearly revealed that viral spreading was substantially increased when tumors were treated with a combination of AdÀDE1B19/55 and radiation (Figure 6a) . Moreover, the E1A protein present in oncolytic Ad may play a role as a potent inducer of p53 protein, ultimately increasing the rate of apoptosis caused by ionizing radiation. As shown by our earlier study, 31 infection with oncolytic Ad resulted in a larger increase in p53 levels relative to untreated cells. According to Portella et al.,
7 E1A-deleted replicationdefective Ad did not enhance cancer cell killing when combined with radiation, supporting the role of E1A in improving anti-tumor efficacy.
The radiation-enhanced efficacy of oncolytic Admediated therapy may also result from increased viral replication owing to ionizing radiation. It has been suggested that irradiation creates a tumor tissue microenvironment that is more favorable to adenoviral infection or replication. Dilley et al. 2 showed that the yield of oncolytic Ad in irradiated cells is higher than in non-irradiated cells. In addition, Zhang et al. 32 showed that ionizing radiation enhances adenoviral uptake by human cancer cell lines. The mechanism responsible for the enhanced uptake of Ad by irradiated cancer cells is related to Dynamin 2. 33 Ionizing radiation upregulates the transcription and cell surface expression of the Dynamin 2 gene, resulting in enhanced infection of Ad in irradiated cells. Combination therapy may also be more successful because each agent targets different cell cycle phases; the M and G 2 phases are more radiosensitive, whereas the S phase is the most responsive to oncolytic virotherapy. 34 Further investigation is needed to evaluate the optimal dosage and administration schedule for oncolytic Ad and radiation. Optimization is paramount, as the rationale for combination therapy is to maximize the ability of the irradiated tumor to replicate oncolytic Ad and to create a tumor microenvironment most favorable to viral infection and subsequent oncolysis. The findings in this study provide strong support for evaluating the potential combination therapy of oncolytic Ad and radiation in a clinical setting.
The absence of additional toxicities affecting weight and general behavior in the combination treatment group relative to the control group is also important. In general, radiotherapy commonly causes both acute and chronic adverse effects that can lead to treatment E1B 19 kDa-deleted oncolytic Ad in combination with radiation J Kim et al interruptions or alterations in the radiotherapy schedule, potentially compromising treatment effectiveness. 35, 36 Oncolytic Ad-mediated cancer gene therapy causes different toxicity profiles, with common systemic reactions such as local inflammation and low-grade fever. 30, 37 The two observed toxicities do not necessarily overlap. Moreover, given the independent mechanism of oncolytic viral tumor cell-killing action and ionizing radiation, cross-resistance is theoretically unlikely, thereby minimizing the evolution of treatment-resistant tumor cells. These findings show that combination treatment could allow lower, less toxic doses of the individual therapies without sacrificing efficacy. Strategies based on combining oncolytic Ad-mediated cancer gene therapy with radiotherapy represent a promising avenue of improving cancer treatment while reducing adverse toxicity.
Materials and methods
Cell lines and Ads
Ad5 E1-transformed human embryonic kidney cell line, HEK293, non-small cell lung carcinoma cell line, A549 (wild type p53), glioma cell line, U343 (wild type p53), hepatocellular carcinoma cell line, Hep3B (mutant p53), and cervical cancer cell line, C33A (mutant p53), were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines (with the exception of Hep3B, which was maintained in modified Eagle's medium (Gibco-BRL, Grand Island, NY, USA)) were cultured in Dulbecco's modified Eagle's medium (Gibco-BRL) with 10% fetal bovine serum (Gilbo-BRL) and penicillin/streptomycin (Gibco-BRL) in a 37 1C incubator with 5% CO 2 . The construction and generation of AdÀDE1B55 and AdÀDE1B19/55 have been previously described. 17 Ads were propagated in 293 cells and purified by CsCl equilibrium centrifugation. Viral particle numbers were calculated from measurements of optical density at 260 nm (OD 260 ), where one absorbency unit is equivalent to 10 12 viral particles per ml, and infectious titers (plaque forming unit per milliliter (PFU ml À1 )) were determined by limiting dilution assay on 293 cells; the MOI was calculated from infectious titers. The viral particle/PFU ratios for AdÀDE1B55 and AdÀDE1B19/55 were 25:1 and 13:1, respectively.
Experimental animals
In vivo anti-tumor experiments were conducted using 6-8-week-old male nude mice (BALB/c-nu) purchased from Charles River Korea (Seoul, South Korea). All mice were maintained in a laminar air flow cabinet under specific pathogen-free conditions. All facilities were approved by the Association of Assessment and Accreditation of Laboratory Animal Care, and all animal experiments were conducted under the institutional guidelines established by the Animal Core Facility at Yonsei University College of Medicine.
Cell viability assay
The inhibition of cancer cell growth by AdÀDE1B55, AdÀDE1B19/55 or radiation alone, or by combination treatment with radiation and AdÀDE1B55 or Ad-DE1B19/55 was analyzed by quantitatively determining cell viability using a 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. After treatment, the medium was removed and fresh medium containing 2 mg ml À1 of MTT (Sigma Chemical Co., St Louis, MO, USA) was added to each well. The cells were then incubated for 4 h at 37 1C in the dark. After removing the MTT solution, the remaining crystals were solubilized with 1 ml of DMSO (dimethyl sulfoxide). After 20 min of incubation, the absorbency was determined using a microplate reader at 540 nm. Cell viability was expressed as a percentage of uninfected control cells. Each experiment was repeated at least thrice.
Fluorescence-activated cell-sorting analysis for apoptotic potential
The induction of apoptosis and cell nuclear damage were determined by propidium iodide and Annexin V staining, and analyzed by flow cytometry. After 3 days of infection with AdÀDE1B55, AdÀDE1B19/55 or radiation alone, or combination treatment with radiation and AdÀDE1B55 or AdÀDE1B19/55, both attached and floating cells were harvested and fixed in 70% ethanol at 4 1C over 24 h. After fixation, the cells were incubated at 4 1C with a mixture of propidium iodide (50 mg ml
À1
) and RNase (0.5 mg ml
) for 15 min, and the fluorescence-activated cell-sorting analysis was then performed. Cells treated with 1 mM camptothecin were used as a positive control. To examine early apoptosis, cells were then labeled with Annexin V-fluorescein isothiocyanate (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. Apoptosis and nuclear damage were quantified on a fluorescence-activated cell sorter (Becton Dickinson, Sunnyvale, CA, USA), and data from 10 000 events were collected for further analysis.
TUNEL assay
Apoptosis was analyzed using the TUNEL assay. Cells were placed on a chamber slide and infected the next day with single and combination treatment with AdÀDE1B55 or AdÀDE1B19/55 and radiation. At 24 h after infection by Ad, one set was irradiated and re-incubated, whereas the other received no irradiation. After an additional 48 h, cells were harvested and processed according to the manufacturer's instructions for the ApopTag kit (Chemicon International, Temecula, CA, USA) for the detection of cleaved deoxyribonucleic acid in situ. The apoptotic cells were counted under magnification ( Â 400) in 10 selected fields. More than 2000 cells were counted to calculate the percentage of TUNEL-positive cells (apoptotic cell ratio).
For the detection of apoptosis in vivo, formalin-fixed tissue sections were deparaffinized in xylene, rehydrated in graded alcohol and transferred to PBS. The slides were treated with proteinase K (20 mg ml À1 ) for 15 min and endogenous peroxidase was blocked using 3% hydrogen peroxide in PBS for 10 min. The samples were washed thrice in distilled water and incubated for 10 min at room temperature with terminal transferase buffer. Excess terminal transferase buffer was drained, and the samples were incubated for 1 h at 37 1C with terminal transferase and biotin-16-dUTP. The samples were then rinsed four times with tris-borate buffer and incubated for 1 h at 37 1C with a 1:400 dilution of peroxidase-conjugated streptavidin. The slides were rinsed with PBS and incubated for 5 min with 3, 3 0 -diaminobenzidine. The sections were then washed thrice with PBS, 
Western blot analysis
The apoptotic signal transduction pathway was analyzed by western blot, as described previously. 31 One day after infection with AdÀDE1B55 or AdÀDE1B19/55 at an MOI of 3, A549 cells were irradiated at 5 Gy. At 6 h after radiation treatment, cell lysates were subjected to western blot analysis using mouse monoclonal antibody to p53 (pAb 1801; Neomarkers, Fremont, CA, USA), mouse monoclonal antibody to phospho-p53 (16G8; Cell Signaling Technology, Beverly, MA, USA), rabbit polyclonal antibodies to phospho-Chk1 and phospho-Chk2 
In vivo anti-tumor efficacy
The right thighs of male athymic nude mice (Charles River Korea) were injected with C33A human cervical cancer cells and then observed for tumor growth. When tumor size reached about 80-100 mm 3 , the animals were randomized and treated by direct injection with PBS, AdÀDE1B55 or AdÀDE1B19/55 at a dose of 1 Â 10 8 PFU on days 0, 2 and 4. For the combination group, the animals were treated locally with a single application of radiation (10 Gy) on the right thigh on day 5 using a clinical linear accelerator (Varian Co., Milpitas, CA, USA). Tumor measurements were taken every 3 days and the volume was calculated as previously described. 29 The survival curve (tumor size 4650 mm 3 ) was plotted against time after treatment (Kaplan-Meier survival function). Differences in survival were considered statistically significant when Po0.05. For the tumor growth delay analysis, the EF was calculated by dividing the normalized tumor growth delay by the absolute growth delay. 21, 22 Absolute growth delay was defined as the time, in days, for tumors to reach 276 mm 3 (the average tumor size of the combination group treated with AdÀDE1B19/55 and radiation at 31 days after treatment) in the treated group minus the mean time to reach 276 mm 3 in the untreated control group (PBS). The normalized tumor growth delay was defined as the time, in days, for tumors to reach 276 mm 3 in mice treated by the combination treatment minus the time, in days, for tumors to reach 276 mm 3 in the group treated with radiation alone.
Immunohistochemistry
Immunohistochemical staining for Ad E1A and p53 protein was performed on paraffin-embedded tissue sections using anti-p53 antibody (Ab-5; Calbiochem) and anti-Ad E1A antibody (13S-5; Santa Cruz Biotechnology), respectively, as described previously. 16 Sections were counterstained with Mayer's hematoxylin.
Statistical analysis
The data were expressed as mean±standard error of the mean (s.e.m.). Statistical comparisons were made using Stat View software (Abacus Concepts, Inc., Berkeley, CA, USA) and the Mann-Whitney test (non-parametric method). Statistical significance was defined as Po0.05. Survival was assessed with the Kaplan-Meier method, and results were compared with a log-rank test (SPSS software, version 12.0, SPSS Inc., Chicago, IL, USA). Differences in survival were considered statistically significant when P values were o0.05.
